Close
Novotech
Jabsco PureFlo 21 Single Use

News

Genezen appoints Senior Director of Business Development to support rapid growth

Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, GMP vector production and analytical testing services, has appointed Laura Jacanin as Senior Director of Business Development. Previously with similar roles at Wuxi,...

19th Edition of BioAsia to focus on Future Readiness of the Life-Sciences Industry; 2-Day event to kick-start on February 24th

19th edition of the Asia’s largest life-sciences and Health Tech forum BioAsia, the annual flagship event of Government of Telangana will be held during February 24th and 25th, 2022 in a virtual format. The theme of this year’s edition...

Vetter’s Peter Soelkner featured on the “Molecule to Market” podcast

Peter Soelkner featured on the “Molecule to Market” podcast Peter Soelkner, one of the managing directors at Vetter, recently sat down with Raman Sehgal of the “Molecule to Market” podcast to share his personal background, the history of Vetter, and...

Indian Pharmaceutical Industry Now And In The Days To Come

It shouldn’t come as a surprise when we call India a global powerhouse when it comes to generic drugs. The Indian pharmaceutical companies cater to more than 50% of world vaccination supplies as well as 40% generic demand in...

Abzena appoints Jim Kennamer as SVP and Site Head of North Carolina

Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Jim Kennamer as Senior Vice President and Site Head of North Carolina. With over 30 years’...

FDA may permit Pfizer COVID vaccine for kids up to 5 years

Dr Anthony Fauci, the chief medical advisor to the White House has gone on to confirm that FDA might as well approve the Pfizer and the BioNTech vaccine for children less than 5 years starting in February 2022. Fauci...

Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant

Pfizer Inc. shared results from multiple studies demonstrating that the in vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets), is maintained against the SARS-CoV-2 variant Omicron. Taken together, these...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »